SAMUEL TIU is a skilled IP litigator in the areas of patents and trade secrets. Sam has litigated IP cases in a wide variety of technologies including industrial and chemical processes, solar and laser technologies, nanotechnology, medical devices, pharmaceuticals, biotechnology, computer animation and graphics, video and data transmission, network technology, and video display technology.
- In re Certain Silicon Photovoltaic Cells and Modules with Nanostructures, Inv. No. 337-TA-1271 – Led the team that successfully defeated the infringement claims against Canadian Solar in a six-patent case relating to silicon nanowires/nanostructures and semiconductor processing.
- Amgen v. Sandoz (D.N.J.) – Successfully tried and obtained a permanent injunction for Amgen in the biotech industry’s first major biosimilar litigation with Sandoz, thus protecting Amgen’s rights to its blockbuster rheumatoid arthritis biopharmaceutical.
- Hanwha v. LONGi Solar Technology – Represented LONGi Solar in its defense against Hanwha’s patents relating to solar cell composition and manufacturing in the ITC and PTAB and secured a finding of non-infringement (ITC) and patent invalidity (PTAB); both affirmed on appeal.
Sam is admitted to practice before the U.S. Patent and Trademark Office and counsels clients on various aspects of intellectual property, including intellectual property procurement strategies, licensing, and due diligence. Managing Intellectual Property named Sam a “Patent Star” from 2019–2023. Before starting his legal career, Sam worked in the biotechnology industry for seven years. He has a technical background in microbiology and molecular genetics, and he is also fluent in Chinese.